San Diego’s weight-loss drugmaker Orexigen Therapeutics Inc. is teaming up with a German distributor that will handle Orexigen’s sales in Germany, France, and Austria.

Orexigen’s new partner, Cheplapharm Arzneimittel GmbH, will be responsible for all commercialization activity and expenses in those markets for Orexigen’s drug, Mysimba (called Contrave in the U.S.).

The German pharmaceutical company has subsidiaries in France and the U.S., and is approved to sell over 150 medicines in over 100 countries.

"Cheplapharm's strong capabilities in weight-management therapy and established relationships in the market make them an ideal partner to bring Mysimba to patients in Germany, France and Austria," said Thomas Cannell, Orexigen’s executive vice president, chief operating officer, and president of global commercial products.

“With this agreement, we now have partnerships covering 48 countries worldwide. In Europe, Mysimba has now launched in 16 countries, and we expect to launch in up to eight more countries by year end."